Johan Lund

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: CANCER MEDICINE. 2023;12(22):20736-20744
Minimal residual disease status is the prognostic determinant following high-dose treatment for patients with multiple myeloma
Nahi H; Afram G; Uttervall K; Lockmer S; Tatting L; Gahrton G; Kashif M; Alici E; Stromberg O; Klimkowska M; Lund J
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2023;111(2):181-190
Impact of newly diagnosed extramedullary myeloma on outcome after first autograft followed by maintenance: A CMWP-EBMT study
Gagelmann N; Eikema D-J; Koster L; Netelenbos T; McDonald A; Stoppa A-M; Fenk R; Anagnostopoulos A; van Gorkom G; Deconinck E; Bulabois C-E; Delforge M; Bunjes D; Arcese W; Remenyi P; Itala-Remes M; Thurner L; Bolaman AZ; Nabil Y; Lund J; Labussiere-Wallet H; Hayden PJ; Beksac M; Schoenland S; Yakoub-Agha I
Article: CYTOTHERAPY. 2023;25(7):763-772
Challenges in αCD38-chimeric antigen receptor (CAR)-expressing natural killer (NK) cell-based immunotherapy in multiple myeloma: Harnessing the CD38dim phenotype of cytokine-stimulated NK cells as a strategy to prevent fratricide
Karvouni M; Vidal-Manrique M; Susek KH; Hussain A; Gilljam M; Zhang Y; Gray JD; Lund J; Kaufmann G; Ljunggren H-G; Ji H; Lundqvist A; Wagner AK; Guo W; Alici E
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2023;72(5):1153-1167
Generation of NK cells with chimeric-switch receptors to overcome PD1-mediated inhibition in cancer immunotherapy
Susek KH; Schwietzer YA; Karvouni M; Gilljam M; Keszei M; Hussain A; Lund J; Kashif M; Lundqvist A; Ljunggren H-G; Nahi H; Wagner AK; Alici E
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2022;109(6):749-754
Conditioning with melphalan 200 mg/m² and subsequent ASCT improves progression-free and overall survival in elderly myeloma patients compared to standard of care
Afram G; Chaireti R; Uttervall K; Luong V; Lund J; Kashif M; Gahrton G; Alici E; Nahi H
Article: CANCER REPORTS. 2022;5(11):e1614
Regional differences in treatment and outcome for myeloma patients in Sweden: A population based Swedish myeloma register study
Walinder G; Genell A; Juliusson G; Svensson R; Santamaria AI; Crafoord J; Carlson K; Knut-Bojanowska D; Veskovski L; Lauri B; Lund J; Turesson I; Hansson M; Blimark CH; Nahi H
Article: CELL REPORTS MEDICINE. 2022;3(2):100508
Autologous NK cells as consolidation therapy following stem cell transplantation in multiple myeloma
Nahi H; Chrobok M; Meinke S; Gran C; Marquardt N; Afram G; Sutlu T; Gilljam M; Stellan B; Wagner AK; Blomberg P; Holmqvist P-H; Walther-Jallow L; Mellstrom K; Liwing J; Gustafsson C; Mansson R; Klimkowska M; Gahrton G; Lund J; Ljungman P; Ljunggren H-G; Alici E
Article: CLINICAL LYMPHOMA, MYELOMA AND LEUKEMIA. 2021;21(10):686-693
IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) Study
Lawless S; Sbianchi G; Morris C; Iacobelli S; Bosman P; Blaise D; Remenyi P; Byrne JL; Mayer J; Apperley J; Lund J; Kobbe G; Schaap N; Isaksson C; Lenhoff S; Basak G; Touzeau C; Wilson KMO; Gonzalez Muniz S; Scheid C; Browne P; Anagnostopoulos A; Rambaldi A; Jantunen E; Kroeger N; Schoenland S; Yakoub-Agha I; Garderet L
Article: AMERICAN JOURNAL OF HEMATOLOGY. 2021;96(8):925-933
Low dose venetoclax as a single agent treatment of plasma cell malignancies harboring t(11;14)
Nahi H; Kashif M; Klimkowska M; Karvouni M; Wallblom A; Gran C; Hauenstein J; Frengen N; Gustafsson C; Afram G; Uttervall K; Lund J; Mansson R; Wagner AK; Alici E
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2021;106(4):546-554
Improved survival in multiple Myeloma patients undergoing autologous stem cell transplantation is entirely in the standard cytogenetic risk groups
Afram G; Susek KH; Uttervall K; Wersall JD; Wagner AK; Luong V; Lund J; Gahrton G; Alici E; Nahi H
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2019;103(3):247-254
Upfront bortezomib, lenalidomide, and dexamethasone compared to bortezomib, cyclophosphamide, and dexamethasone in multiple myeloma
Uttervall K; Bruchfeld JB; Gran C; Walinder G; Mansson R; Lund J; Gahrton G; Alici E; Nahi H
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2019;25(1):34-40
A Pilot, Exploratory, Randomized, Phase II Safety Study Evaluating Tumor Cell Mobilization and Apheresis Product Contamination in Patients Treated with Granulocyte Colony-Stimulating Factor Alone or Plus Plerixafor
Nahi H; Celanovic M; Liu Q; Lund J; Peceliunas V
Article: PLOS ONE. 2019;14(2):e0211927
Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma
Nahi H; Chrobok M; Gran C; Lund J; Gruber A; Gahrton G; Ljungman P; Wagner AK; Alici E
Article: CANCER MEDICINE. 2018;7(6):2256-2268
Lenalidomide versus lenalidomide plus dexamethasone prolonged treatment after second-line lenalidomide plus dexamethasone induction in multiple myeloma
Lund J; Gruber A; Lauri B; Duru AD; Blimark C; Swedin A; Hansson M; Forsberg K; Ahlberg L; Carlsson C; Waage A; Gimsing P; Vangsted AJ; Frolund U; Holmberg E; Gahrton G; Alici E; Hardling M; Mellqvist U-H; Nahi H
Article: CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2018;81(1):183-193
Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial
Falk IJ; Lund J; Green H; Gruber A; Alici E; Lauri B; Blimark C; Mellqvist U-H; Swedin A; Forsberg K; Carlsson C; Hardling M; Ahlberg L; Lotfi K; Nahi H
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2016;96(1):46-54
Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21
Nahi H; Vatsveen TK; Lund J; Heeg BMS; Preiss B; Alici E; Moller MB; Wader KF; Moller HEH; Groseth LA; Ostergaard B; Dai HY; Holmberg E; Gahrton G; Waage A; Abildgaard N
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2015;94(4):355-362
TP53 mutations and MDM2^SNP309 identify subgroups of AML patients with impaired outcome
Falk IJ; Willander K; Chaireti R; Lund J; Nahi H; Hermanson M; Green H; Lotfi K; Soderkvist P
Article: PLOS ONE. 2015;10(9):e0138248
Deletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple Myeloma
Duru AD; Sutlu T; Wallblom A; Uttervall K; Lund J; Stellan B; Gahrton G; Nahi H; Alici E
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2014;164(5):684-693
Improved survival in myeloma patients: starting to close in on the gap between elderly patients and a matched normal population
Liwing J; Uttervall K; Lund J; Aldrin A; Blimark C; Carlson K; Enestig J; Flogegard M; Forsberg K; Gruber A; Kviele HH; Johansson P; Lauri B; Mellqvist U-H; Swedin A; Svensson M; Nasman P; Alici E; Gahrton G; Aschan J; Nahi H
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2014;92(1):19-25
Addition of thalidomide to melphalan and prednisone treatment prolongs survival in multiple myeloma - a retrospective population based study of 1162 patients
Lund J; Uttervall K; Liwing J; Gahrton G; Alici E; Aschan J; Holmberg E; Nahi H
Article: PLOS ONE. 2014;9(7):e101819
The Use of Novel Drugs Can Effectively Improve Response, Delay Relapse and Enhance Overall Survival in Multiple Myeloma Patients with Renal Impairment
Uttervall K; Duru AD; Lund J; Liwing J; Gahrton G; Holmberg E; Aschan J; Alici E; Nahi H
Article: ACTA HAEMATOLOGICA. 2013;130(1):7-15
A Combination Regimen of Bortezomib, Cyclophosphamide and Betamethasone Gives Quicker, Better and More Durable Response than VAD/CyBet Regimens: Results from a Swedish Retrospective Analysis
Uttervall K; Admasie J; Alici E; Lund J; Liwing J; Aschan J; Barendse M; Deneberg S; Mellqvist U-H; Carlson K; Nahi H
Visa fler

Alla övriga publikationer

Letter: EUROPEAN JOURNAL OF HAEMATOLOGY. 2023;110(2):224-225
Response to Caravita di Toritto and Rago
Chaireti R; Uttervall K; Luong V; Lund J; Kashif M; Gahrton G; Alici E; Nahi H; Afram G
Letter: AMERICAN JOURNAL OF HEMATOLOGY. 2021;96(11):E443-E446
Antibody response to COVID-19 mRNA vaccine (Comirnaty) in myeloma patients treated with high-dose melphalan and/or immunotherapy
Lockmer S; Uttervall K; Kashif M; Svard C; Malmsten K; Fletcher-Torres E; Alici E; Lund J; Nahi H
Letter: AMERICAN JOURNAL OF HEMATOLOGY. 2021;96(3):E63-E65
Dynamic follow-up of smoldering multiple myeloma identifies a subset of patients at high risk of progression
Gran C; Luong V; Bruchfeld JB; Liwing J; Afram G; Lund J; Usmani S; Alici E; Nahi H
Letter: BRITISH JOURNAL OF HAEMATOLOGY. 2016;174(3):473-477
Re-challenging with anti-CD38 monotherapy in triple-refractory multiple myeloma patients is a feasible and safe approach
Alici E; Chrobok M; Lund J; Ahmadi T; Khan I; Duru AD; Nahi H

Anställningar

Anknuten till Forskning, Medicin, Huddinge, Karolinska Institutet, 2023-2026

Examina och utbildning

Medicine Doktorsexamen, Institutionen för medicin, Huddinge, Karolinska Institutet, 2016

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI